# US 2023/0053881 A1 · Neuregulin for the treatment and/or prevention of tumors of the nervous system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053881 A1
- Document ID: US20230053881A1
- Status: Published application
- Kind: A1
- Application number: 17/878,221
- Filed: 2022-08-01
- Published: 2023-02-23
- Earliest claimed: 2016-04-19
- Assignees: Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli)
- Applicants: Leibniz-Institut Fur Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli)
- Inventors: Alexander Schulz; Helen Morrison
- Web page: https://patentgrep.com/patent/US20230053881A1

## CPC

- A61K 38/18: Growth factors; Growth regulators
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A polypeptide is provided that includes an EGF-like domain of a neuregulin protein. A nucleic acid encoding for the polypeptide is also provided. A gene therapy vector inclusive of the nucleic acid and genetically modified cells expressing said polypeptide are also provided. The medical use of the polypeptide, the nucleic acid, the gene therapy vector or the cell for the treatment of tumours of the nervous system are also provided. In particular the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours are provided.

## Claims

### Claim 1

A method for treating and/or preventing a tumor of the nervous system in a subject, comprising administering a nucleic acid molecule to the subject, wherein the nucleic acid molecule encodes a polypeptide that comprises an EGF-like domain of a neuregulin protein.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the polypeptide is a soluble fragment of a neuregulin protein.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the polypeptide comprises an amino acid sequence according to one of SEQ ID NO 9-14 or an amino acid sequence with an identity of at least 80% to any one of SEQ ID NO 9-14.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the polypeptide consists of an amino acid sequence according to SEQ ID NO 9 or of an amino acid sequence with an identity of at least 80% to SEQ ID NO 9.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the tumor is a tumor of the cranial or peripheral nerves.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the tumor is a malignant nerve sheath tumor.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the tumor is a schwannoma.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the tumor is a neurofibroma.

### Claim 9 (depends on 1)

The method according to claim 1, for treating and/or preventing medical conditions associated with one or more of genetic deficiency in neurofibromatosis type 1, neurofibromatosis type 2, or neurofibromatosis type 3.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule comprises a gene therapy vector.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the gene therapy vector is a viral vector.

### Claim 12 (depends on 11)

The method according to claim 11, wherein viral vector is selected from the group consisting of a moloney murine leukemia virus (MMLV), an adenoviral vector, a lentiviral vector, an adenovirus-associated viral (AAV) vector, a pox virus vector, a herpes simplex virus vector or human immunodeficiency virus vector (HIV-1).

### Claim 13 (depends on 10)

The method according to claim 10, wherein the gene therapy vector is a non-viral vector.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the gene therapy vector is transferred by electroporation or injection of nucleic acid molecule into the subject.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the gene therapy vector is a plasmid DNA expression vector driven by a eukaryotic promoter, or liposomes encapsulating the vector.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the gene therapy vector is configured for inducible or conditional expression of the polypeptide.

### Claim 17 (depends on 1)

The method according to claim 1, comprising administering a cell to the subject, wherein the cell is genetically modified to comprise the nucleic acid molecule according to claim 1.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule is configured to incorporate into the genome of a host cell of the subject.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the composition is administered intravenously to the subject.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the composition is administered locally to the site of the tumor.
